Search

Showing "11154" results for ""

HIV-positive former IDUs have poorer immune response to HAART

Core group of patients with drug resistant HIV engaging in risky sex identified by US study

Higher than expected incidence of HIV found in injecting drug users in London

Keeping track of patients and drugs in rural Haiti: electronic system is practical

HIV protease inhibitors may also check malaria

Roche will not go ahead with nelfinavir 625mg formulation in Europe: cites production problems

Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

Early virologic failure with ddI/tenofovir plus nevirapine or efavirenz

Kaletra effective and well tolerated in PI-experienced patients

Once-daily abacavir receives approval in Europe

Infection with multi-drug resistant virus is lifelong, Canadian expert argues

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

High resistance levels seen in treated Ugandans: cost of therapy blamed

Truvada receives scientific approval in Europe

Double boosted protease inhibitors generate interest at Glasgow conference

Rates of TB treatment interruption unaffected by HIV infection or HAART

AZT resistance suppression mutations can also reduce tenofovir resistance, test tube study shows (corrected)

Atazanavir/ritonavir shows comparable efficacy to Kaletra at 96 weeks for PI-experienced patients

Receive the latest HIV research and conference news

Showing "11154" results for ""

HIV-positive former IDUs have poorer immune response to HAART

Core group of patients with drug resistant HIV engaging in risky sex identified by US study

Higher than expected incidence of HIV found in injecting drug users in London

Keeping track of patients and drugs in rural Haiti: electronic system is practical

HIV protease inhibitors may also check malaria

Roche will not go ahead with nelfinavir 625mg formulation in Europe: cites production problems

Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

Early virologic failure with ddI/tenofovir plus nevirapine or efavirenz

Kaletra effective and well tolerated in PI-experienced patients

Once-daily abacavir receives approval in Europe

Infection with multi-drug resistant virus is lifelong, Canadian expert argues

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

High resistance levels seen in treated Ugandans: cost of therapy blamed

Truvada receives scientific approval in Europe

Double boosted protease inhibitors generate interest at Glasgow conference

Rates of TB treatment interruption unaffected by HIV infection or HAART

AZT resistance suppression mutations can also reduce tenofovir resistance, test tube study shows (corrected)

Atazanavir/ritonavir shows comparable efficacy to Kaletra at 96 weeks for PI-experienced patients

Receive the latest HIV research and conference news